# A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

> **NCT03884829** · PHASE1 · TERMINATED · sponsor: **Cyclacel Pharmaceuticals, Inc.** · enrollment: 7 (actual)

## Conditions studied

- AML, Adult
- Myelodysplastic Syndromes
- ALL, Adult
- CML, Refractory
- CLL, Refractory

## Interventions

- **DRUG:** CYC140

## Key facts

- **NCT ID:** NCT03884829
- **Lead sponsor:** Cyclacel Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-25
- **Primary completion:** 2021-11-29
- **Final completion:** 2023-10-19
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Switch to oral formulation of CYC140 (plogosertib)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03884829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03884829, "A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03884829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*